Answers are grounded in this paper and cite their sources.
HIV-associated lipodystrophy has become a major challenge in the treatment of HIV infection. Recombinant human growth hormone has shown clinical effectiveness in therapy for growth hormone-deficient disorders and HIV-associated lipodystrophy, but its association with a variety of adverse effects has led to the development of human growth hormone-releasing factor analogs. Tesamorelin, a synthetic growth hormone-releasing factor, has been developed for the potential treatment of HIV-associated lipodystrophy. A multicenter, randomized, placebo-controlled, Phase III clinical trial demonstrated that tesamorelin was a beneficial treatment strategy for HIV-associated lipodystrophy with a good safety profile and a positive effect on reducing visceral fat and improving lipid profiles.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: